The National Alliance of Advocates
for Buprenorphine Treatment
Buprenorphine (Suboxone®, Subutex®3, Zubsolv®4, Bunavail™5, Probuphine®6) is an opioid medication used to treat opioid addiction in the privacy of a physician's office.1 Buprenorphine can be dispensed for take-home use, by prescription.1 This, in addition to the pharmacological and safety profile of buprenorphine, makes it an attractive treatment for patients addicted to opioids.2
What is Zubsolv®?
Zubsolv® is a schedule III buprenorphine/naloxone combination medication specifically indicated (and FDA approved) for the treatment of opioid addiction. Along with Suboxone®, its generic equivalents, Subutex® (discontinued in the US), its generic equivalents, Zubsolv is a medication subject to DATA-2000.
FDA approved on July 3, 2013 and commercially launched in September 2013, Zubsolv is the first brand name competitor to Suboxone. Manufacturer copay card available - up to $225 off
Zubsolv has a higher bioavailability than Suboxone and as a result comes in different doses than Subxone or generics. Zubsolv comes in sublingual tablet sizes of 5.7-mg/1.4-mg (buprenorphine/naloxone), and 1.4-mg/0.36-mg (buprenorphine/naloxone) both have equal bioavailability to 8mg/2mg and 4mg/1mg of competing buprenorphine/naloxone products, respectively. Sub-to-Zub dose conversion tool
UPDATE: On March 6, 2015 Orexo US, Inc. announced the FDA approval of the new 8.6mg/2.1mg dosage strength of ZUBSOLV®. This corresponds to 12mg/3mg of generic bup/nx dosing.
Zubsolv is individually packaged to reduce accidental pediatric exposure.
See the Zubsolv website for more info: zubsolv.com
Back to FAQs
The Purpose of Buprenorphine Treatment:
To suppress the debilitating symptoms of cravings and withdrawal, enabling the patient to engage in therapy, counseling and support, so they can implement positive long-term changes in their lives which develops into the new healthy patterns of behavior necessary to achieve sustained addiction remission. - explain -
The National Alliance of Advocates for Buprenorphine Treatment is a non-profit organization charged with the mission to:
- Educate the public about the disease of opioid addiction and the buprenorphine treatment option.
- Help reduce the stigma and discrimination associated with patients with addiction disorders.
- Serve as a conduit connecting patients in need of treatment to buprenorphine treatment providers.
- U.S. Food and Drug Administration, FDA Talk Paper, T0238, October 8, 2002, Subutex and Suboxone approved to treat opiate dependence.
- Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockville, Md: Substance Abuse and Mental Health Services Administration, 2004.
- Subutex Discontinued in the US market in late 2011.
- Zubsolv (bup/nx sublingual tablet) FDA approved 7/3/2013 see buprenorphine pipeline graphic -in pharmacies now.
- Bunavail (bup/nx bucal film) FDA approved 6/6/2014 see buprenorphine pipeline graphic -in pharmacies now.
- Probuphine FDA approved 5/26/2016 - FDA Probuphine press release